Track topics on Twitter Track topics that are important to you
US clinical stage pharmaceutical company Aerie Pharmaceuticals has entered into a research, development and license agreement with Dutch life sciences group DSM. The agreement includes an option to license DSM’s bio-erodible polymer implant technology for evaluating its application to deliver certain Aerie compounds that are initially focused on retinal diseases.
Original Article: Aerie and DSM in Eye Diseases PactNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...